Cancer heterogeneity: Origins and implications for genetic association studies

Trends in Genetics

Volumn 28, Issue 11, 2012, Pages 538-543

  Urbach, Davnah ^a   Lupien, Mathieu ^a,b   Karagas, Margaret R ^a   Moore, Jason H ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Cancer heterogeneity; Genetic association studies; Genetic predispositions; Somatic mutations

Indexed keywords

CANCER SUSCEPTIBILITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETIC ASSOCIATION STUDIES; GENETIC HETEROGENEITY; HUMANS; MUTATION; NEOPLASMS; PHENOTYPE;

EID: 84867693534     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2012.07.001     Document Type: Review

References (80)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Podlaha O., et al. Evolution of the cancer genome. Trends Genet. 2012, 28:155-163.
3. Ashworth A., et al. Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38.
4. Berdasco M., Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev. Cell 2010, 19:698-711.
5. Shlien A., et al. Excessive genome DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11264-11269.
6. Fletcher O., Houlston R.S. Architecture of inherited susceptibility to common cancer. Nat. Rev. Cancer 2010, 10:353-361.
7. Malkin D. Predictive genetic testing for childhood cancer: taking the road less traveled by. J. Pediatr. Hematol. Oncol. 2004, 26:546-548.
8. Frank S.A. Genetic predisposition to cancer - insights from population genetics. Nat. Rev. Genet. 2004, 5:764-771.
9. Freedman M.L., et al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat. Genet. 2011, 43:513-518.
10. Manolio T.A., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
11. Yung C.H., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2070-2075.
12. Crespi B., Summers K. Evolutionary biology of cancer. Trends Ecol. Evol. 2005, 20:545-552.
13. Michor F., et al. Dynamics of cancer progression. Nat. Rev. Cancer 2004, 4:197-206.
14. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
15. Greenman C., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
16. Futreal P.A., et al. A census of human cancer genes. Nat. Rev. Cancer 2004, 4:177-183.
17. Eng C., Mulligan L.M. Mutation of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum. Mutat. 1997, 9:97-109.
18. Sjöblom T., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
19. Parsons D.W., et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011, 331:435-439.
20. Lee W., et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010, 465:473-477.
21. Navin N., et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-95.
22. Stephens P.J., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
23. Jones S., et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4283-4288.
24. Shah S.P., et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med. 2009, 360:2719-2729.
25. Olivier M., et al. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2:a001008.
26. Karakas B., et al. Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer 2006, 94:455-459.
27. Frank S.A. Somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1725-1730.
28. Merlo L.M.F., et al. Cancer as an evolutionary and ecological process. Nature 2006, 6:924-935.
29. Yachida S., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
30. Stratton M.R., et al. The cancer genome. Nature 2009, 458:719-724.
31. Marusyk A., et al. Intra-tumor heterogeneity: a looking glass for cancer. Nat. Rev. Cancer 2012, 12:323-334.
32. Sakai W., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1121.
33. Edwards S.L., et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1116.
34. Wagner A. Neutralism and selectionism: a network-based reconciliation. Nat. Rev. Genet. 2008, 9:965-974.
35. Anderson K., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-362.
36. Sprouffske K., et al. Accurate reconstruction of the temporal order of mutations in neoplastic progression. Cancer Prev. Res. 2011, 4:1135-1144.
37. Gerlinger M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
38. Notta F., et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-368.
39. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
40. Geyer F.C., et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J. Pathol. 2010, 220:562-573.
41. Da Silva L., et al. Tumor heterogeneity in a follicular carcinoma of thyroid: a study by comparative genomic hybridization. Endocr. Pathol. 2011, 22:103-107.
42. Morgan G.J., et al. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 2012, 12:335-348.
43. Czene K., et al. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family-cancer database. Int. J. Cancer 2002, 99:260-266.
44. Stratton M.R. Exploring the genomes of cancer cells: progress and promise. Science 2011, 331:1553-1558.
45. Bradford P.T., et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J. Med. Genet. 2011, 48:168-176.
46. de Jong M.M., et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1332-1352.
47. Hsieh F.I., et al. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br. J. Cancer 1999, 81:537-541.
48. Lannon C.L., Sorensen P.H.B. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin. Cancer Biol. 2005, 15:215-223.
49. Yan X.J., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 2011, 43:309-315.
50. Puente X.S., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukemia. Nature 2011, 475:101-105.
51. Galvan A., et al. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet. 2010, 26:132-141.
52. Clark A.G., et al. Determinants of the success of whole-genome association testing. Genome Res. 2005, 15:1463-1467.
53. Singleton A.B., et al. Towards a complete resolution of the genetic architecture of disease. Trends Genet. 2010, 26:438-442.
54. Park J., et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 2010, 42:570-575.
55. Prahallad A., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-1004.
56. Chanock S.J., et al. Replicating genotype-phenotype associations. Nature 2007, 447:655-660.
57. Antoniou A.C., et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat. Genet. 2010, 42:885-892.
58. Pusztai L., et al. Molecular classification of breast cancer: limitations and potential. Oncologist 2006, 11:868-877.
59. Mackay A., et al. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserved agreement. J. Natl. Cancer Inst. 2011, 103:662-673.
60. Weigelt B., et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010, 11:339-349.
61. Curtis C., et al. The genomic and transcriptomic architecture of 2000 breast tumors reveals novel subgroups. Nature 2012, 10.1038/nature10983.
62. Guedj M., et al. A refined molecular taxonomy of breast cancer. Oncogene 2012, 31:1196-1206.
63. Abu-Asab M., et al. Evolutionary medicine: a meaningful connection between omics, disease, and treatment. Proteomics Clin. Appl. 2008, 2:122-134.
64. Lu J., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
65. Fackler M.J., et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 2011, 71:6195-6207.
66. Ladouceur M., et al. The empirical power of rare variant association methods: results from Sanger sequencing in 1,998 individuals. PLoS Genet. 2012, 8:e1002496.
67. Ziegler A., et al. Biostatistical aspects of genome-wide association studies. Biom. J. 2008, 50:8-28.
68. Wright J.B., et al. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single nucleotide polymorphism in colorectal cancer cells. Mol. Cell. Biol. 2010, 30:1411-1420.
69. Gaulton K.J., et al. A map of open chromatin in human pancreatic islets. Nat. Genet. 2010, 42:255-259.
70. Zhang X., et al. Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17p24.3 prostate cancer risk locus. Genome Res. 2012, 10.1101/gr.135665.111.
71. Wojcik S.E., et al. Non-coding RNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis 2010, 31:208-215.
72. Bader A.G., et al. The promise of MicroRNA replacement therapy. Cancer Res. 2010, 70:7027-7030.
73. Ding L., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
74. Hou Y., et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012, 148:873-885.
75. Xu X., et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012, 148:886-895.
76. Norquist B., et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 2011, 29:1-9.
77. Ding J., et al. Feature based classifiers for somatic mutation detection in tumour-normal paired sequencing data. Bioinformatics 2011, 28:167-175.
78. Cowper-Sal Iari R., et al. Layers of epistasis: genome-wide regulatory networks and network approaches to genome-wide association studies. Wiley Interdiscip. Rev. Syst. Biol. Med. 2010, 3:513-526.
79. Michor F., et al. What does physics have to do with cancer?. Nat. Rev. Cancer 2011, 11:657-670.
80. Shepherd R., et al. Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database 2011, 10.1093/database/bar018.